Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid versus fibrinogen for bleeding control in posterior lumbar spine fusion surgery
IRCT20210415050983N4Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of tranexamic acid and Fibrinogen human in lumbosacral disc disease (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Intraoperative bleeding rate. Started Apr 2023; status: completed.
02
Drugs
tranexamic acidFibrinogen human
03
Conditions
lumbosacral disc disease
Beyond the preview
Go deeper on IRCT20210415050983N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210415050983N4.